FDA Section 361 Compliance Guidelines for Cell Products

FDA section 361 compliance guidelines for human cell and tissue products (HCT/Ps) govern tissue-based therapies regulated under 21 CFR Part 1271 without requiring pre-market approval. To qualify under Section 361, a tissue product must undergo minimal manipulation, be designated solely for homologous use, and operate without systemic metabolic action or combination with unapproved agents. Clinical practices sourcing allografts must rigorously audit tissue vendors to verify donor screening, facility registration, and chain-of-custody compliance to mitigate legal and operational risk.

Understanding 21 CFR 1271 and Section 361 HCT/P Criteria

Under Title 21 of the Code of Federal Regulations (CFR) Part 1271, the U.S. Food and Drug Administration (FDA) establishes a risk-based framework for human cells, tissues, and cellular and tissue-based products. Section 361 of the Public Health Service (PHS) Act applies to products that pose lower biological risk because they meet four specific regulatory criteria. When a tissue product fails to satisfy even one of these criteria, it falls under Section 351, reclassifying it as a drug, biological product, or medical device that requires pre-market approval (IND/BLA).

To maintain status as a Section 361 HCT/P, the product must satisfy all four of the following requirements:

1. Minimal Manipulation: The processing of the tissue does not alter the original relevant biological characteristics relating to the tissue's utility for repair, reconstruction, or supplementation.
2. Homologous Use Only: The product is intended to perform the same basic function or functions in the recipient as in the donor.
3. No Unapproved Combinations: The tissue is not combined with another article (such as a drug or synthetic device), except for water, crystalloids, or sterilizing, preserving, or storage agents.
4. No Systemic Effect: The product does not depend upon the metabolic activity of living cells for its primary function, or, if it does, it is intended solely for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

Medical practice managers evaluating biologics must understand that compliance is determined by both how the product is manufactured and how it is marketed and used in the clinic.

Minimal Manipulation: Structural vs. Non-Structural Tissue

The FDA distinguishes between structural tissues (such as bone, skin, fascia, and connective tissue) and non-structural tissues (such as blood cells, plasma, and amniotic fluid). Minimal manipulation for structural tissue means that processing does not alter its structural utility. For non-structural tissue, minimal manipulation means processing does not alter the biological characteristics relevant to its function.

Enzymatic digestion, cell isolation, and extensive chemical processing generally cause a product to exceed minimal manipulation. When evaluating tissue vendors, administrative leaders should confirm that processing methods preserve native tissue structures rather than isolating active cellular fractions.

The Homologous Use Standard

Homologous use requires that the donor tissue perform the same basic repair or structural function in the recipient patient that it performed in the donor. For example, using an amniotic membrane allograft as a structural wound cover or anatomical barrier aligns with homologous use. However, marketing or using the same tissue to treat systemic neurodegenerative conditions, metabolic disorders, or non-structural internal pathologies violates the homologous use standard, shifting the product into Section 351 drug regulation.

Practices partnering with regenerative medicine doctors must audit both vendor marketing collateral and internal clinical protocols to ensure claims align strictly with homologous intent.

Operational Risk and Compliance Sourcing Checklist

Establishing an compliant procurement workflow requires practice administrators to vet potential supplier credentials and documentation thoroughly. Relying on vendor marketing statements alone is insufficient during a regulatory audit.

Use this operational checklist when evaluating any prospective human cell or tissue supplier:

• FDA Establishment Registration: Request and verify the vendor's active FDA Form 3356 registration status via the FDA Human Cell and Tissue Establishment Registration (HCTERS) database.
• State Tissue Bank Licensure: Ensure the tissue processor holds valid tissue bank licensing in the state where the facility is located as well as the state where your practice operates.
• Donor Screening & Testing Protocols: Confirm that donor selection criteria meet strict infectious disease screening regulations under 21 CFR 1271 Subpart C.
• Certificate of Analysis (CoA): Verify that every tissue lot includes a lot-specific CoA detailing sterility testing, endotoxin screening, and structural integrity parameters.
• Homologous Marketing Verification: Review vendor educational literature, website content, and labeling to confirm the manufacturer makes no Section 351 drug claims (e.g., claiming systemic disease mitigation or cellular regeneration of unrelated organs).
• Chain-of-Custody & Cold Chain Storage: Confirm that shipping protocols include validated temperature-monitoring devices and clear storage handling instructions.

For additional context on compliant procurement standards, practices can review technical summaries published in our publications section.

Clinical vs. Practice Management Perspectives on Section 361 Compliance

Maintaining regulatory compliance requires coordination between clinical providers and administrative staff. Each group views Section 361 guidelines through a different operational lens.

Clinical Considerations: Patient Safety and Structural Function

For physicians and clinical directors, Section 361 compliance directly impacts clinical decision-making and patient safety:

• Structural Application: Clinicians must ensure allografts are applied in anatomical sites where structural support, cushioning, or tissue coverage is required.
• Documentation of Clinical Rationale: Patient charts must document the structural need for the tissue allograft, ensuring the treatment plan reflects homologous use.
• Adverse Event Reporting: Clinicians must follow clear protocols for reporting suspected tissue contamination or adverse reactions directly to the tissue bank and FDA MedWatch system.

Practice Operations: Vendor Due Diligence and Recordkeeping

For practice managers and procurement officers, Section 361 compliance centers on operational risk reduction and administrative traceability:

• Traceability Logs: Regulations require practices to maintain detailed tracking logs linking the specific tissue lot number to the patient medical record and treatment date.
• Ten-Year Record Retention: FDA regulations require tissue distribution and administration records to be retained for a minimum of 10 years.
• Cost per Treatment Analysis: Practice leaders must calculate true procurement costs, factoring in required specialized cold storage equipment, shipping fees, and potential liability insurance implications.
• Vendor Standardization: Limiting procurement to verified, compliant suppliers prevents compliance gaps caused by ordering from unvetted distributors.

Addressing regulatory requirements alongside questions documented in our clinical practice faq helps streamline onboarding for new clinical services.

What This Means for Your Practice

Navigating Section 361 guidelines requires proactive internal governance to protect your practice reputation and patient safety while providing high-quality biological options. Practice administrators should take the following immediate steps:

1. Audit Existing Biologics Inventory: Inspect all current cellular and tissue products to verify active FDA registration numbers, CoAs, and storage parameters.
2. Review Marketing and Patient Materials: Remove any marketing copy, consent forms, or website language that implies systemic cures, cellular reprogramming, or non-homologous outcomes.
3. Update Inventory and Charting Protocols: Standardize chart templates to capture tissue lot numbers, expiration dates, donor identifiers, and structural placement details.
4. Establish Vendor Review Cadences: Require all biological product suppliers to submit updated tissue bank licenses and regulatory compliance attestations annually.

To discuss compliant biological procurement, donor tracking workflows, or tissue allograft sourcing for your facility, contact our team of specialists for a detailed operational consultation.